Fulcrum Therapeutics, Inc. (FULC)
FULCNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$3.72
0.0000 (0.00%) today
At the close, Nov 10, 4:00 PM ET. After hours $3.72 –
- Market cap
- $284.14m
- P/E
- –
- EPS, last 4 quarters
- $-1.08
- Dividend yield
- –
- Day range
- $3.68 to $3.76
- 52-week range
- $2.83 to $15.74
- Average volume
- 1.38m
- Previous close
- $3.72
Earnings
next estimate $-0.1000Next report Nov 11, 2026
Sep 2025
-6.9%
Dec 2025
0.0%
Mar 2026
+19.4%
Jun 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$21.86m | -$22.69m | -$22.19m | -$29.31m |
| Net income | -$19.59m | -$20.33m | -$18.89m | -$26.18m |
News
8 latest- Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75Fintel · 23 hours ago
- Fulcrum Therapeutics Consensus Price Target Raised 11.22% to $7.75Fintel · Oct 2, 2026
- Slate Doses First Participant In Phase 1 Study Of SLTE-1009; Topline Data Anticipated Mid-2027 RTTNews · Aug 27, 2026
- Weekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks RTTNews · Aug 21, 2026
- Notable Monday Option Activity: FULC, BAC, VIAVBNK Invest · Aug 17, 2026
- Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech DealMarketBeat · Aug 17, 2026
- Fulcrum-Slate Merger Announced; $245M Financing Boosts Migraine Pipeline; Shares Rise RTTNews · Aug 17, 2026
- Thursday 7/16 Insider Buying Report: FULC, ECATBNK Invest · Jul 16, 2026
The company
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. For more information, visit www.fulcrumtx.com and follow it on X (@FulcrumTx) and LinkedIn.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- fulcrumtx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.